Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Stork

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Pediatric Blood & Cancer|July 21, 2006
Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942)Shana S Jacobs, Linda C Stork, Bruce C Bostrom, et al.
Pediatric Blood & Cancer|February 14, 2009
Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS)V Koneti Rao, Susan Price, Katie Perkins, et al.
Cancer Chemotherapy and Pharmacology|April 26, 2001
Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group studyE S Lowe, B J Kitchen, G Erdmann, et al.
Blood|April 13, 2006
Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology GroupYousif Matloub, Susan Lindemulder, Paul S Gaynon, et al.
Blood Advances|June 5, 2019
Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology GroupYousif Matloub, Karen R Rabin, Lingyun Ji, et al.
Pediatric Blood & Cancer|June 14, 2016
Navigating your career path in pediatric hematology/oncology: On and off the beaten trackPatrick A Zweidler-McKay, Mary-Jane Staba Hogan, Rima Jubran, et al.
Leukemia|November 15, 2016
Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemiaC Dafflon, V J Craig, H Méreau, et al.
Blood|May 13, 2011
Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology GroupYousif Matloub, Bruce C Bostrom, Stephen P Hunger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2018
Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II TrialLia Gore, Pamela R Kearns, Maria Lucia de Martino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2019
Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331Kelly W Maloney, Meenakshi Devidas, Cindy Wang, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Pediatric Blood & Cancer|July 21, 2006
Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942)Shana S Jacobs, Linda C Stork, Bruce C Bostrom, et al.
Pediatric Blood & Cancer|February 14, 2009
Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS)V Koneti Rao, Susan Price, Katie Perkins, et al.
Cancer Chemotherapy and Pharmacology|April 26, 2001
Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group studyE S Lowe, B J Kitchen, G Erdmann, et al.
Blood|April 13, 2006
Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology GroupYousif Matloub, Susan Lindemulder, Paul S Gaynon, et al.
Blood Advances|June 5, 2019
Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology GroupYousif Matloub, Karen R Rabin, Lingyun Ji, et al.
Pediatric Blood & Cancer|June 14, 2016
Navigating your career path in pediatric hematology/oncology: On and off the beaten trackPatrick A Zweidler-McKay, Mary-Jane Staba Hogan, Rima Jubran, et al.
Leukemia|November 15, 2016
Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemiaC Dafflon, V J Craig, H Méreau, et al.
Blood|May 13, 2011
Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology GroupYousif Matloub, Bruce C Bostrom, Stephen P Hunger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2018
Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II TrialLia Gore, Pamela R Kearns, Maria Lucia de Martino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2019
Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331Kelly W Maloney, Meenakshi Devidas, Cindy Wang, et al.
Pageof 5